Abstracts tagged "Pharmacoepidemiology"

Abstract Number: 1214 • ACR Convergence 2024
All-Cause Mortality in Patients with Chronic Musculoskeletal Pain Using Pregabalin or Duloxetine: A Retrospective Cohort Study in US Veterans
Sachalee Campbell¹, Laura L. Daniel², Alyson L. Dickson³, Otis Wilson³, C. Michael Stein³, Puran Nepal⁴, Adriana M. Hung⁵ and Cecilia P. Chung², ¹University of Miami/ Jackson Health System, Miami, FL, ²University of Miami, Miami, FL, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Vanderbilt University Medical Center, Vanderbilt, TN, ⁵Veterans Administration Tennessee Valley Healthcare System, Nashville, TN
Background/Purpose: Musculoskeletal pain affects more than 10% of the general population. Recent trends in managing chronic musculoskeletal pain have favored non-opioid analgesics, for example, pregabalin,…
Abstract Number: 1215 • ACR Convergence 2024
Mortality in US Veterans with Musculoskeletal Conditions Using Cyclobenzaprine or Baclofen
Maria Intriago¹, Puran Nepal², Laura L. Daniel¹, Alyson L. Dickson³, Otis Wilson³, C. Michael Stein³, Adriana M. Hung⁴ and Cecilia P. Chung¹, ¹University of Miami, Miami, FL, ²Vanderbilt University Medical Center, Vanderbilt, TN, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Veterans Administration Tennessee Valley Healthcare System, Nashville, TN
Background/Purpose: Cyclobenzaprine is a commonly-used centrally-acting muscle relaxant; it has been approved for short-term treatment of muscle spasms associated with acute musculoskeletal pain despite limited…
Abstract Number: 0152 • ACR Convergence 2024
Hydroxychloroquine and Chloroquine Retinopathy in Hispanic Patients with Rheumatic Diseases
Janett Riega Torres¹, Karina Palomo-Arnaud², Gabriel Figueroa-Parra¹, Fernando Morales Wong¹, Jesús Hernán González Cortés¹, Jesus Mohamed Hamsho¹, Jorge Esquivel-Valerio¹, Dionicio Galarza-Delgado³ and Karim Mohamed Noriega¹, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, San Nicolás de los Garza, Mexico, ³UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: Antimalarial drugs like hydroxychloroquine (HCQ) and chloroquine (CQ) are among the most frequently prescribed medications in Rheumatology. Retinal toxicity is an unwanted side effect…
Abstract Number: 1270 • ACR Convergence 2024
Association of Disease-Modifying Anti-Rheumatic Drug Selection with Hospitalized Infection in Youth with Childhood-Onset Systemic Lupus Erythematosus
Jordan Roberts¹, Anna Faino², Marshall Brown³, Gabrielle Alonzi⁴, Mersine Bryan⁵, Cordelia Burn⁶, Joyce Chang⁴, Jonathan Cogen⁷, Nidhi Naik⁸, Kareena Patel⁹, Emily Zhang⁴, Mary Beth Son¹⁰ and Esi Morgan¹, ¹Seattle Children's Hospital, Seattle, WA, ²Seattle Children's Research Institute, Core for Biostatistics, Epidemiology and Analytics in Research, Seattle, ³Core for Biostatistics, Epidemiology and Analytics in Research, Seattle Children's Research Institute, Seattle, WA, ⁴Boston Children's Hospital, Boston, MA, ⁵Division of Hospital Medicine, Seattle Children's Hospital, Seattle, WA, ⁶Seattle Children's Hospital, Boston Children's Hospital, Seattle, ⁷Seattle Children’s Hospital, Seattle, WA, ⁸Seattle children's hospital, Bothell, WA, ⁹Seattle Children's Hospital, Seattle, ¹⁰Boston Children's Hospital, Brookline, MA
Background/Purpose: Youth with childhood-onset systemic lupus erythematosus (cSLE) have increased risk of serious infection. It is unknown how much of this risk is due to…
Abstract Number: 0159 • ACR Convergence 2024
Prevalence and Potential Factors Associated with Polypharmacy in Individuals with Systemic Lupus Erythematosus
Jianing Yang¹, Jinoos Yazdany², S. Sam Lim³, Brad Pearce³ and Laura Plantinga⁴, ¹Highland Hospital, AHS, San Leandro, CA, ²UCSF, San Francisco, CA, ³Emory University, Atlanta, GA, ⁴University of California, San Francisco, San Francisco, CA
Background/Purpose: Polypharmacy is associated with an increased risk of adverse drug effects and medication nonadherence. However, the prevalence of polypharmacy and the medications and factors…
Abstract Number: 1439 • ACR Convergence 2024
Risk of Hip and Spine Fractures in Axial Spondyloarthritis Is Associated with Treatment Class
Devin Driscoll¹, Navya George², S. Reza Jafarzadeh³, Christine Peloquin³, Jean Liew³ and Maureen Dubreuil⁴, ¹Boston Medical Center, Boston, MA, ²Boston University Medical Center Internal Medicine Residency Program, Boston, MA, ³Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁴Section of Rheumatology, Boston University School of Medicine, Boston, MA
Background/Purpose: Individuals with axial spondyloarthritis (axSpA) have a risk of fracture that is nearly double that of the general population, possibly related to chronic inflammation.…
Abstract Number: 0268 • ACR Convergence 2024
Weight Loss Induced by Anti-obesity Medications and Gout Among Overweight and Obesity Individuals: A Population-based Cohort Study
Jie Wei¹, Yilun Wang², Nicola Dalbeth³, Junqing Xie⁴, Jing Wu⁵, Chao Zeng⁶, Guanghua Lei⁷ and Yuqing Zhang⁸, ¹Department of Orthopaedics, Xiangya Hospital, Central South University; Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University; Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University; Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China (People's Republic), ²Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China (People's Republic), ³University of Auckland, Auckland, New Zealand, ⁴Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁵Hunan Key Laboratory of Joint Degeneration and Injury, Changsha, China (People's Republic), ⁶Department of Orthopaedics, Xiangya Hospital, Central South University; Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University; Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University; Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China (People's Republic), ⁷Department of Orthopaedics, Xiangya Hospital, Central South University; Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University; Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China (People's Republic), ⁸Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School; The Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Weight loss is conditionally recommended for gout management; however, the magnitude of the effect of weight loss on incident gout and recurrent gout flares…
Abstract Number: 1713 • ACR Convergence 2024
Comparisons of Non-TNFi Biologic and Targeted Synthetic DMARDs in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Propensity Score-Matched Study Using National Veterans Affairs Data
Halie Frideres¹, Christopher Wichman², Jianghu Dong³, Punyasha Roul⁴, Yangyuna Yang², Joshua Baker⁵, Michael George⁶, Tate Johnson², Jorge Rojas⁷, Sauer brian⁸, grant Cannon⁹, Scott Matson¹⁰, Jeffrey Curtis¹¹, Ted Mikuls² and Bryant England², ¹UNMC Department of Rheumatology, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³University of Nebraska Medical Center, Omaha, ⁴UNMC, Omaha, NE, ⁵Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Seattle VA, Mexico, Mexico, ⁸Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁹University of Utah and Salt Lake City VA, Salt Lake City, UT, ¹⁰University of Kansas, Kansas City, MO, ¹¹University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Recent RA-interstitial lung disease (RA-ILD) treatment guidelines noted a paucity of evidence on the comparative effectiveness and safety of DMARDs in RA-ILD. Previously, TNFi…
Abstract Number: 0509 • ACR Convergence 2024
Trends in Initiation of Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among Commercially-Insured US Adults, 2001-2021
Lydia Lee¹, Jeffrey Sparks², Priyanka Yalamanchili¹, Daniel B. Horton³, Zeba Khan⁴, Joseph Barone⁴ and Chintan Dave⁵, ¹Rutgers University, New Brunswick, NJ, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ³Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research; Department of Biostatistics and Epidemiology, Rutgers School of Public Health; Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁴Rutgers University, New Brunswick, ⁵Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research; Center for Health Outcomes, Policy & Economics, Rutgers Ernest Mario School of Pharmacy and Rutgers School of Public Health, New Brunswick, NJ
Background/Purpose: Despite the increasing availability of newer RA therapies, there is a paucity of data comprehensively evaluating long-term trends for individual DMARDs in the US.…
Abstract Number: 1717 • ACR Convergence 2024
Early Antimalarial Adherence Reduces Future Hospitalization Cost in Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients: Evidence from a Population-based Study
Md Rashedul Hoque¹, Diane Lacaille², J. Antonio Avina-Zubieta², Mary A. De Vera³, Yi Qian⁴, John Esdaile⁵ and Hui Xie⁶, ¹Simon Fraser University, Vancouver, BC, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ³University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, ⁴University of British Columbia, Vancouver, Canada, ⁵Arthritis Research Canada, Vancouver, BC, Canada, ⁶Arthritis Research Canada, Simon Fraser University, Vancouver, BC, Canada
Background/Purpose: To examine the association between antimalarial (AM) adherence and hospitalization costs among newly diagnosed rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients.Methods: We…
Abstract Number: 0529 • ACR Convergence 2024
Discontinuation of Targeted Disease-Modifying Antirheumatic Agents in Older Patients with Rheumatoid Arthritis: Retrospective Analysis of Medicare Data
Yinan Huang¹, Shadi Bazzazzadehgan², Sebastian Bruera³ and Sandeep Agarwal³, ¹University of Mississippi School of Pharmacy, Oxford, MS, ²University of Mississippi School of Pharmacy, Oxford, ³Baylor College of Medicine, Houston
Background/Purpose: Individuals with rheumatoid arthritis (RA) may discontinue b/tsDMARDs due to treatment failure, adverse events or costs. Little is known about b/tsDMARDs discontinuation among Medicare…
Abstract Number: 1756 • ACR Convergence 2024
What Is the Impact of Prior TNF Inhibitor Treatment on the Time to Achieve Low Disease Activity and the Durability of Low Disease Activity? Real-world Results Based on 17 858 European Patients with Axial Spondyloarthritis Initiating a TNF Inhibitor or an IL-17A Inhibitor
Jette Heberg¹, Stylianos Georgiadis², Marion Pons³, Anne Gitte Loft⁴, Brigitte Michelsen⁵, Louise Linde³, Daniela DiGuiseppe⁶, Simon Horskjær Rasmussen³, Mehrdad Kazemi³, Gary Macfarlane⁷, Gareth Jones⁷, Karin Laas⁸, Sigrid Vorobjov⁹, Isabel Castrejon¹⁰, Ziga Rotar¹¹, Katja Perdan-Pikmajer¹¹, Ladislav Šenolt¹², Jana Baranová¹³, Bente Glintborg¹⁴, Adrian Ciurea¹⁵, Miguel Bernardes¹⁶, Paula Valente¹⁷, Bjorn Gudbjornsson¹⁸, Gerdur Gröndal¹⁸, Gunnstein Bakland¹⁹, Catalin Codreanu²⁰, Corina Mogosan²⁰, Florenzo Iannone²¹, Roberto Caporali²², Johan Karlsson Wallman²³, Vappu Rantalaiho²⁴, Ritva Peltomaa²⁵, Karel Pavelka²⁶, Pavel Horak²⁷, Diogo Esperança Almeida²⁸, Sara Dias Rodrigues²⁹, Lykke Oernbjerg², Mikkel Ostergaard³⁰ and Merete Hetland³¹, ¹Rigshospitalet Glostrup, København V, Denmark, ²Rigshospitalet Glostrup, Glostrup, Hovedstaden, Denmark, ³Rigshospitalet Glostrup, Glostrup, Denmark, ⁴Aarhus University Hospital and Aarhus University, Horsens, Denmark, ⁵Rigshospitalet Glostrup, Diakonhjemmet Hospital and Sørlandet Hospital, Copenhagen, Denmark, ⁶Karolinska Institutet, Stockholm, ⁷University of Aberdeen, Aberdeen, United Kingdom, ⁸East-Tallinn Central Hospital, Tallinn, Estonia, ⁹National Institute for Health Development, Tallinn, Estonia, ¹⁰Hospital General Universitario Gregorio Marañón and Complutense University of Madrid, Madrid, Spain, ¹¹University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ¹²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ¹³Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic, ¹⁴DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark, ¹⁵University Hospital Zurich, Zürich, Switzerland, ¹⁶São João Hospital Center and FMUP, Lisboa, Portugal, ¹⁷Rheumatology Department, Hospital de São Sebastião, Centro Hospitalar de Entre o Douro e Vouga, Santa Maria da Feira, Portugal, ¹⁸Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ¹⁹Department of Rheumatology, University Hospital North Norway, Tromsø, Norway, ²⁰University of Medicine and Pharmacy, Bucharest, Romania, ²¹Rheumatology Unit- University of Bari "Aldo Moro", IT, Bari, Italy, ²²Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ²³Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Skane Lan, Sweden, ²⁴Tampere University Hospital, Tampere University and Kanta-Häme Central Hospital, Tampere, Finland, ²⁵Helsinki University Hospital and University of Helsinki, Helsinki, Finland, ²⁶Institute of Rheumatology and Charles University, Praha, Czech Republic, ²⁷3rd Department of Internal Medicine - Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc & Palacky University Olomouc, Faculty of Medicine and Dentistry, Olomouc, Olomoucky kraj, Czech Republic, ²⁸Hospital de Braga, Braga, Portugal, ²⁹Serviço de Reumatologia, Hospital Egas Moniz, Unidade Local de Saúde Lisboa Ocidental, Lisboa, Portugal, ³⁰Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ³¹Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark
Background/Purpose: Tumour necrosis factor inhibitors (TNFi) and Interleukin-17Ai inhibitors (IL-17Ai) have shown effectiveness in achieving low disease activity (LDA) in patients with axial spondyloarthritis (axSpA).…
Abstract Number: 0806 • ACR Convergence 2024
Rotavirus Vaccine in Offspring Exposed to Tumour Necrosis Factor Inhibitors During the Third Trimester Does Not Increase Diarrhea-Associated Healthcare Events
Leah K. Flatman¹, Sasha Bernatsky², Isabelle Malhamé³, Yvan St-Pierre⁴, Olga Basso¹, Anick Bérard⁵ and Evelyne Vinet³, ¹McGill University, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University Health Center, Montreal, QC, Canada, ⁵Université de Montréal, Montreal, QC, Canada
Background/Purpose: Until recently, best practice guidelines recommended withholding rotavirus vaccine in offspring exposed in utero to any TNFi until 6 months of age due to fears of…
Abstract Number: 1868 • ACR Convergence 2024
Opioid Prescription Rates in Patients with Radiographic Axial Spondyloarthritis in the US Between 2008-2021: A Joinpoint Regression Analysis
Berk Degirmenci¹, Christine Peloquin², Sara Lodi¹, Pedro M Machado³, S. Reza Jafarzadeh², Tuhina Neogi², Lianne S Gensler⁴, Maureen Dubreuil⁵ and Jean Liew², ¹Boston University, Boston, MA, ²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ³Department of Neuromuscular Diseases and Centre for Rheumatology, University College London, London, United Kingdom, ⁴Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵Section of Rheumatology, Boston University School of Medicine, Boston, MA
Background/Purpose: Current axial spondyloarthritis (axSpA) guidelines do not provide recommendations for opioids in pain management. Opioid use is common in axSpA, despite widespread uptake of…
Abstract Number: 0907 • ACR Convergence 2024
Association of Rare and Common Genetic Variants in MOCOS with Inadequate Response to Allopurinol
Niamh Fanning¹, Murray Cadzow², Ruth Topless³, Chris Frampton⁴, Nicola Dalbeth⁵, Tony Merriman⁶ and Lisa Stamp⁴, ¹University of Otago, Christchurch, New Zealand, ²University of Otago, Dunedin 9054, New Zealand, ³University of Otago, Dunedin, New Zealand, ⁴University of Otago, Christchurch, Christchurch, New Zealand, ⁵University of Auckland, Auckland, New Zealand, ⁶University of Alabama at Birmingham, Homewood, AL
Background/Purpose: The minor allele of the common rs2231142 (Q141K) ABCG2 variant predicts inadequate response to allopurinol urate lowering therapy (ULT). We hypothesize that additional variants in genes…

1
2
3
…
7
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.